|
UA76934C2
(en)
|
1996-10-04 |
2006-10-16 |
Chugai Pharmaceutical Co Ltd |
Reconstructed human anti-hm 1.24 antibody, coding dna, vector, host cell, method for production of reconstructed human antibody, pharmaceutical composition and drug for treating myeloma containing reconstructed human anti-hm 1.24 antibody
|
|
US6986890B1
(en)
|
1996-11-21 |
2006-01-17 |
Kyowa Hakko Kogyo Co., Ltd. |
Anti-human VEGF receptor Flt-1 monoclonal antibody
|
|
US6428965B1
(en)
|
1997-07-17 |
2002-08-06 |
The Johns Hopkins University |
Screening assays for the interaction of semaphorins and neuropilins
|
|
CA2313607A1
(en)
|
1997-12-09 |
1999-06-17 |
Children's Medical Center Corporation |
Antagonists of neuropilin receptor function and use thereof
|
|
AU1810899A
(en)
|
1997-12-09 |
1999-06-28 |
Children's Medical Center Corporation |
Neuropilins and use thereof in methods for diagnosis and prognosis of cancer
|
|
WO1999029858A1
(en)
|
1997-12-09 |
1999-06-17 |
Children's Medical Center Corporation |
Soluble inhibitors of vascular endothelial growth factor and use thereof
|
|
JP2002530066A
(ja)
|
1998-11-19 |
2002-09-17 |
スミスクライン・ビーチャム・コーポレイション |
Ｒｈａｍｍアンタゴニスト抗体
|
|
CN1423700A
(zh)
|
2000-03-24 |
2003-06-11 |
麦克美特股份公司 |
含有针对nkg2d受体复合物的表位的结合位点的多功能多肽
|
|
US7183388B2
(en)
*
|
2001-03-30 |
2007-02-27 |
The Regents Of The University Of California |
Anti-MUC-1 single chain antibodies for tumor targeting
|
|
US20030113324A1
(en)
|
2001-10-01 |
2003-06-19 |
Kari Alitalo |
Neuropilin/VEGF-C/VEGFR-3 materials and methods
|
|
US20040214766A1
(en)
|
2001-10-01 |
2004-10-28 |
Kari Alitalo |
VEGF-C or VEGF-D materials and methods for treatment of neuropathologies
|
|
US20040028685A1
(en)
|
2002-05-10 |
2004-02-12 |
Kinch Michael S. |
EphA2 monoclonal antibodies and methods of use thereof
|
|
UA89348C2
(ru)
|
2002-10-16 |
2010-01-25 |
Евро-Селтик С.А. |
Изолированное моноклональное антитело, которое связывает клеточно-ассоциированный полипептид са 125/о772р
|
|
SI2301965T1
(sl)
|
2002-10-16 |
2015-07-31 |
Purdue Pharma L.P. |
Protitelesa, ki vežejo celično- povezan CA 125 / O722P in metode uporabe le-teh
|
|
US20050106667A1
(en)
*
|
2003-08-01 |
2005-05-19 |
Genentech, Inc |
Binding polypeptides with restricted diversity sequences
|
|
US7982011B2
(en)
*
|
2003-11-25 |
2011-07-19 |
The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Mutated anti-cd22 antibodies and immunoconjugates
|
|
WO2006001888A2
(en)
|
2004-04-16 |
2006-01-05 |
Acuity Pharmaceuticals Inc |
Compositions and methods for inhibiting angiogenesis
|
|
EP3072522B1
(en)
|
2005-01-06 |
2019-04-24 |
Novo Nordisk A/S |
Anti-kir combination treatments and methods
|
|
EP1739092A1
(en)
|
2005-06-28 |
2007-01-03 |
I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale |
Peptidic antagonists of class III semaphorins/neuropilins complexes
|
|
US20100130904A1
(en)
|
2005-07-18 |
2010-05-27 |
Trustees Of Boston University |
Method to inhibit proliferation and growth of metastases
|
|
EP1915170A1
(en)
|
2005-08-16 |
2008-04-30 |
Klinikum der Universität Regensburg |
Use of neuropilin-2 antagonists
|
|
UA96139C2
(uk)
|
2005-11-08 |
2011-10-10 |
Дженентек, Інк. |
Антитіло до нейропіліну-1 (nrp1)
|
|
US7420040B2
(en)
|
2006-02-24 |
2008-09-02 |
Arius Research Inc. |
Cytotoxicity mediation of cells evidencing surface expression of TROP-2
|
|
EP2639315A1
(en)
|
2007-05-11 |
2013-09-18 |
The Johns Hopkins University |
Biomarkers for melanoma
|
|
US8648173B2
(en)
*
|
2007-05-17 |
2014-02-11 |
Genentech, Inc. |
Inhibition of tumor metastasis by anti neuropilin 2 antibodies
|
|
CN101743253B
(zh)
|
2007-05-17 |
2013-05-08 |
健泰科生物技术公司 |
神经毡蛋白片段与神经毡蛋白抗体复合物的晶体结构
|
|
AR068723A1
(es)
|
2007-10-05 |
2009-12-02 |
Glaxo Group Ltd |
Proteina que se une a antigenos que se une a il-23 humana y sus usos
|
|
EP2641606A1
(en)
|
2008-05-27 |
2013-09-25 |
Pluristem Ltd. |
Methods of treating inflammatory colon diseases
|
|
FR2935385B1
(fr)
|
2008-08-27 |
2013-04-19 |
Diaclone |
Induction de l'expression de p53 par neutralisation de la neuropiline-2 pour le traitement des cancers
|
|
CA2745961A1
(en)
|
2008-12-04 |
2010-06-10 |
The Regents Of The University Of California |
Materials and methods for determining diagnosis and prognosis of prostate cancer
|
|
WO2010074266A1
(ja)
|
2008-12-26 |
2010-07-01 |
協和発酵キリン株式会社 |
抗cd4抗体
|
|
EP2403531A4
(en)
|
2009-03-05 |
2013-02-27 |
Abbott Lab |
IL-17 BINDING PROTEINS
|
|
EP2408905B1
(en)
|
2009-03-16 |
2017-05-10 |
Pangu Biopharma Limited |
Compositions and methods comprising histidyl-trna synthetase splice variants having non-canonical biological activities
|
|
CN102459335B
(zh)
|
2009-04-17 |
2015-11-25 |
伊缪纳斯制药株式会社 |
特异性结合Aβ寡聚体的抗体及其用途
|
|
SG179070A1
(en)
|
2009-09-11 |
2012-04-27 |
Genentech Inc |
Method to identify a patient with an increased likelihood of responding to an anti-cancer agent
|
|
WO2011042548A1
(en)
|
2009-10-09 |
2011-04-14 |
Sanofi-Aventis |
Polypeptides for binding to the "receptor for advanced glycation endproducts" as well as compositions and methods involving the same
|
|
EP2488874A4
(en)
|
2009-10-13 |
2013-08-14 |
Univ Johns Hopkins |
BIOMARKERS FOR THE IDENTIFICATION OF MELANOMOTUM CELLS
|
|
TWI667346B
(zh)
|
2010-03-30 |
2019-08-01 |
中外製藥股份有限公司 |
促進抗原消失之具有經修飾的FcRn親和力之抗體
|
|
BR112012024713B1
(pt)
*
|
2010-03-31 |
2021-02-17 |
Boehringer Ingelheim International Gmbh |
anticorpo humanizado, seus usos e composição farmacêutica que o compreende
|
|
US9243057B2
(en)
|
2010-08-31 |
2016-01-26 |
The Regents Of The University Of California |
Antibodies for botulinum neurotoxins
|
|
US20130236467A1
(en)
|
2010-11-24 |
2013-09-12 |
Jeremy Griggs |
Multispecific antigen binding proteins targeting hgf
|
|
JP6104794B2
(ja)
|
2011-04-18 |
2017-03-29 |
国立大学法人 東京大学 |
抗ｉｔｍ２ａ抗体を用いる癌の診断および治療
|
|
KR20140114415A
(ko)
|
2012-01-13 |
2014-09-26 |
제넨테크, 인크. |
Vegf 길항제로의 치료를 위한 환자를 확인하기 위한 생물학적 마커
|
|
NZ629296A
(en)
|
2012-01-27 |
2016-06-24 |
Prothena Biosciences Ltd |
Humanized antibodies that recognize alpha-synuclein
|
|
WO2013116742A1
(en)
|
2012-02-01 |
2013-08-08 |
Mayo Foundation For Medical Education And Research |
Predicting responses to androgen deprivation therapy and methods for treating prostate cancer
|
|
HUE033369T2
(en)
|
2012-11-20 |
2017-11-28 |
Sanofi Sa |
Anti-ceacam5 antibodies and uses thereof
|
|
CN105102480B
(zh)
|
2012-12-24 |
2019-04-16 |
艾伯维公司 |
催乳素受体结合蛋白及其用途
|
|
US20160000873A1
(en)
|
2013-02-14 |
2016-01-07 |
Ucl Business Plc |
Agents which induce lymphangiogenesis for use in the treatment of cystic kidney disease
|
|
HK1219740A1
(zh)
|
2013-03-15 |
2017-04-13 |
Biogen Ma Inc. |
使用抗αVβ5抗体治疗和预防急性肾损伤
|
|
CN105378075B
(zh)
|
2013-03-15 |
2022-04-05 |
Atyr 医药公司 |
组氨酰-trna合成酶-fc缀合物
|
|
AU2014293670B2
(en)
|
2013-07-23 |
2019-08-01 |
Immunomedics, Inc. |
Antibody-SN-38 immunoconjugates with a CL2A linker
|
|
WO2015095686A1
(en)
|
2013-12-20 |
2015-06-25 |
Trustees Of Boston University |
Assays and methods relating to the treatment of melanoma
|
|
WO2016039801A1
(en)
|
2014-01-31 |
2016-03-17 |
Boehringer Ingelheim International Gmbh |
Novel anti-baff antibodies
|
|
KR20160131082A
(ko)
|
2014-03-12 |
2016-11-15 |
프로테나 바이오사이언시즈 리미티드 |
Lg1-3에 특이적인 항-라미닌4 항체
|
|
MX2016015569A
(es)
|
2014-06-02 |
2017-04-25 |
Children´S Medical Center Corp |
Metodos y composiciones para inmunomodulacion.
|
|
KR20170040249A
(ko)
|
2014-08-12 |
2017-04-12 |
노파르티스 아게 |
항-cdh6 항체 약물 접합체
|
|
US9732148B2
(en)
*
|
2014-10-16 |
2017-08-15 |
Genentech, Inc. |
Anti-α-synuclein antibodies and methods of use
|
|
IL256800B2
(en)
|
2015-07-14 |
2023-04-01 |
Immunext Inc |
An anti-cd154 antibody with improved binding, functional and safety properties and use in human immunotherapy
|
|
EP3464349A4
(en)
*
|
2016-05-23 |
2020-08-26 |
New York University |
COMPOSITIONS AND METHODS ASSOCIATED WITH ANTIBODIES TARGETING STAPHYLOCCAL LEUCOTOXINS
|
|
WO2018102589A2
(en)
|
2016-11-30 |
2018-06-07 |
Atyr Pharma, Inc. |
Anti-hrs antibodies and combination therapies for treating cancers
|
|
WO2018195302A1
(en)
|
2017-04-19 |
2018-10-25 |
Bluefin Biomedicine, Inc. |
Anti-vtcn1 antibodies and antibody drug conjugates
|
|
CN110536694A
(zh)
|
2017-04-20 |
2019-12-03 |
Atyr 医药公司 |
用于治疗肺部炎症的组合物和方法
|
|
WO2019075472A1
(en)
|
2017-10-13 |
2019-04-18 |
A&G Pharmaceutical, Inc. |
MONOCLONAL AND CONJUGATED ANTIBODIES AGAINST THE PROSTAGLANDIN F2 RECEPTOR INHIBITOR AND USES THEREOF
|
|
US12365916B2
(en)
|
2017-10-30 |
2025-07-22 |
Miltenyi Biotec B.V. & Co. KG |
Adapter-based retroviral vector system for the selective transduction of target cells
|
|
JP7399880B2
(ja)
|
2018-01-26 |
2023-12-18 |
ジェンザイム・コーポレーション |
ＦｃＲｎへの増強された結合及び延長された半減期を有するＦｃ変異体
|
|
CA3096222A1
(en)
|
2018-04-06 |
2019-10-10 |
Atyr Pharma, Inc. |
Compositions and methods comprising anti-nrp2 antibodies
|
|
MX2021011489A
(es)
|
2019-04-01 |
2021-10-22 |
Jiangsu Hengrui Medicine Co |
Anticuerpo anti-claudina 18.2 y utilizacion del mismo.
|
|
EP4034238B1
(en)
|
2019-09-23 |
2025-09-24 |
Centro Nacional de Investigaciones Cardiovasculares Carlos III (F.S.P.) |
Antibodies for the diagnosis and/or treatment of atherosclerosis
|
|
CN114746120B
(zh)
|
2019-10-03 |
2024-07-30 |
Atyr医药公司 |
包含抗nrp2抗体的组合物和方法
|
|
JP2023519962A
(ja)
|
2020-03-31 |
2023-05-15 |
アレクトル エルエルシー |
抗ｍｅｒｔｋ抗体及びその使用方法
|
|
JP7705674B2
(ja)
|
2021-10-15 |
2025-07-10 |
学校法人 芝浦工業大学 |
イメージセンサデータ制御システム
|
|
WO2023076998A1
(en)
|
2021-10-27 |
2023-05-04 |
Atyr Pharma, Inc. |
COMPOSITIONS AND METHODS COMPRISING ANTI-NRP2a ANTIBODIES
|
|
WO2023245117A2
(en)
|
2022-06-17 |
2023-12-21 |
Atyr Pharma, Inc. |
Compositions and methods comprising anti-nrp2 antibodies
|